Skip to content

Clinical trials

Phase 1/2 Precursor Cell Lymphoblastic Leukemia-Lymphoma trials with unknown status

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Precursor Cell Lymphoblastic Leukemia-Lymphoma Phase: Phase 1/2 Status: Unknown status Clear all

25 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20051
20102
20132
20152
20166
20173
20182
20191
20213
20222
20231

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status25

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
PersonGen BioTherapeutics (Suzhou) Co., Ltd.3
Wuhan Sian Medical Technology Co., Ltd3
Federal Research Institute of Pediatric Hematology, Oncology and Immunology2
Acibadem University1
Callisto Pharmaceuticals1
Chinese PLA General Hospital1
Ciusss de L'Est de l'Île de Montréal1
Diane George1
Hospital Universitario San Ignacio1
Institute of Hematology & Blood Diseases Hospital, China1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma25
Leukemia, Myeloid, Acute8
Lymphoma, Non-Hodgkin5
Myelodysplastic Syndromes5
Leukemia, Lymphocytic, Chronic, B-Cell4
Leukemia, Prolymphocytic, B-Cell3
Lymphoma3
Lymphoma, B-Cell3
Lymphoma, Follicular3
Lymphoma, Large B-Cell, Diffuse3

Trials

Showing 1 to 25 of 25. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.